Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyメs COVID-19…
On Apr. 7, 2021, the National Institutes of Health (NIH) announced that a clinical trial was underway to…
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it had awarded $3 billion…
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
On Apr. 5, 2021, Anixa Biosciences announced that based on Proof of Concept animal study results, it was…
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the…
On Apr. 1, 2021, the U.S. Food and Drug Administration (FDA) announced two revisions regarding the number of…
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
On Apr. 1, 2021, Pfizer and BioNTech announced updated topline results from analysis of 927 confirmed symptomatic cases…
On Apr. 1, 2021, Arbutus Biopharma, X-Chem and Proteros Biostructures announced hat they had entered into a discovery…
On Apr. 1, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that an investigational vaccine designed to…
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
On Mar. 31, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA,…
On Mar. 31, 2021, Pfizer and BioNTech announced that, in a Phase 3 trial in adolescents 12 to…